Clinical trials: Therapy Resistant Depression
Depression, Neurofeedback
Neurofeedback In Treatment Resistant Depression
The investigators evaluate the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04078438
- Testing
- neurofeedback augmentation, treatment as usual
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Yeungnam University Hospital
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Treatment Resistant Depression
Dorsomedial Prefrontal Cortex and the Antidepressant Efficacy of Theta Burst Stimulation in Depressed Patients
This study evaluates an association between different dosage and the antidepressant efficacy of theta burst stimulation in patients with treatment-resistant depression.
- Trial name
- NCT04037592
- Testing
- Active standardized iTBS-DMPFC, Active high-dosage iTBS-DMPFC
- Where
- Taiwan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Late Life Depression
A Breathing-Based Meditation Intervention for Patients With Treatment Resistant Late Life Depression
Late-life depression affects 2-8% of seniors and causes high rates of caregiver distress and risk of suicide. To exacerbate the problem, antidepressants, the cornerstone of therapy, are resistant in 55-80% of this population.
- Trial name
- NCT03368560
- Testing
- Sudarshan Kriya Yoga
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Major Depressive Disorder, Treatment Resistant Depression
The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression
Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and…
- Trial name
- NCT06163625
- Testing
- Repetitive Transcranial Magnetic Stimulation, Research Interview, Questionnaires, Brain Scan
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Treatment Resistant Depression, Visual Perceptual Weakness
Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
Major depressive disorder (MDD) exhibit reduced visual motor perception, which affects prognosis. Metabolic substance changes and abnormal neural activity in the middle temporal visual area (MT) mediate this perceptual…
- Trial name
- NCT06044324
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Treatment Resistant Depression
Accelerated Intermittent Theta Burst Stimulation for Depressed Patients During the Covid-19 Pandemic
Repetitive Transcranial Magnetic Stimulation (rTMS) using intermittent theta burst stimulation (iTBS) has been found to be a non inferior protocol to standard rTMS for the treatment of major depressive disorder.
- Trial name
- NCT04935489
- Testing
- Intermittent Theta Burst Stimulation (form of repetitive transcranial magnetic stimulation) given in an accelerated form
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ontario Shores Centre for Mental Health Sciences
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depression Moderate, Major Depression Severe
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in older age patients diagnosed with Major Depressive Episode, Major Depression, and Bipolar Disorder…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07740694
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Treatment-Resistant Major Depressive Disorder
Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)
Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression…
- Trial name
- NCT07052058
- Testing
- Tocilizumab, Normal Saline (0.9% NaCl)
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Late Life Depression, Cognitive Decline
Dopaminergic Dysfunction in Late-Life Depression
Late-Life Depression (LLD), or depression in older adults, often presents with motivational deficits, deficits in performance in cognitive domains including processing speed and executive dysfunction, and mobility impairments.
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa
- Trial name
- D3 (NCT04469959)
- Testing
- L-Dopa
- Where
- 2 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Major Depressive Disorder
MRI Studies of Emotion in Depression
The purpose of this study is to research the effects of ketamine on brain function in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT02429011
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as…
- Trial name
- NCT02994433
- Testing
- Nitrous Oxide, MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Treatment-Resistant Depression
Early Identification of TRD and Construction and Clinical Validation of NTBS Precision Technology
The goal of this clinical trial is to learn about the characteristics, identify early and intervene effectively in time in Treatment-Resistant Depression.
- Trial name
- NCT05777876
- Testing
- non-invasive transcranial deep brain stimulation, Motor cortex stimulation, non-invasive transcranial deep brain stimulation with closed-loop
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Healthy, Major Depressive Disorder
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome.
- Conditions
- Healthy, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06480201
- Testing
- Ketamine, Saline
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Depression, Treatment Resistant Depression
Investigational TMS Treatment for Depression
This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.
- Trial name
- NCT03175887
- Testing
- TMS
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- White River Junction Veterans Affairs Medical Center
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depressive Disorder
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression
This Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group trial will estimate whether concurrent fluoxetine alters the antidepressant effect, acute psychedelic experience, or safety of a…
- Trial name
- COGUNILA (NCT06898606)
- Testing
- Psilocybin and Psilocyn, Psychotherapy-assisted session, Fluoxetine
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Federal University of Latin American Integration